PharmaMar will present final data on PM1183 during the 18th World Lung Conference in Japan
PharmaMar (MSE:PHM) will present the final efficacy and safety data obtained from the Phase I/II trial combining PM1183 (lurbinectedin) with doxorubicin in relapsed small-cell lung...






